In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Otsuka Pharmaceutical Co. Ltd.

Division of Otsuka Holdings Co. Ltd.
www.otsuka.co.jp/en/

Latest From Otsuka Pharmaceutical Co. Ltd.

UK's AstronauTx Gets Cash For Alzheimer's Programs

The Dementia Discovery Fund is backing the UCL spin-off's efforts to develop therapies that modulate astrocyte function.

Financing Neurology

Vadadustat Emerges As Japan HIF-PHI Leader With First Filing Globally

Competition intensifies in novel anemia therapy space in Japan with first filing globally for Akebia/Mitsubishi Tanabe’s contender vadadustat, which could see its first launch worldwide in the country.

Japan Commercial

Blonanserin On Course As First Atypical For Adolescent Schizophrenia In Japan

Dainippon drug likely to become first atypical to be approved for adolescent schizophrenia in Japan following planned filing based on positive new Phase III results.

Japan Clinical Trials

Positive Results Move Anemia Contender Enarodustat Towards First Filing

Japanese firms unveil pivotal top-line results that pave way for first filing of novel anemia therapy within new class of agents, but competition is high and timings remain unclear.

Japan Clinical Trials
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register